Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025

Read more at globenewswire.com